Neueste Versuche

EudraCT Number: 2021-003474-31 Sponsor Protocol Number: COAV101B12301 Start Date: 2023-06-01
Sponsor Name: Novartis Pharma AG
Full Title: A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to
Medical condition: Spinal Muscular Atrophy
Disease: Version SOC Term Classification Code Term Level
20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DK (Ongoing) GR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002292-11 Sponsor Protocol Number: VX20-880-101 Start Date: 2023-06-01
Sponsor Name: Vertex Pharmaceuticals Incorporated
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Medical condition: Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
21.1 10027433 - Metabolism and nutrition disorders 10081605 Severe hypoglycemia LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Temporarily Halted) NO (Temporarily Halted) NL (Ongoing) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002679-12 Sponsor Protocol Number: EOCRC1-22 Start Date: 2023-06-01
Sponsor Name: Enterome SA
Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c...
Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy .
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010033 Colorectal cancer stage II PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003792-41 Sponsor Protocol Number: DAROTAXEL Start Date: 2023-05-26
Sponsor Name: Erasmus MC
Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
Medical condition: metastatic castration-resistant prostate cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002312-23 Sponsor Protocol Number: LY06006/MRCT-301 Start Date: 2023-05-25
Sponsor Name: Shandong Boan Biotechnology Co., Ltd.
Full Title: A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmeno...
Medical condition: Postmenopausal osteoporosis
Disease: Version SOC Term Classification Code Term Level
20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: BG (Ongoing) CZ (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003475-42 Sponsor Protocol Number: GTAEXS617-001 Start Date: 2023-05-23
Sponsor Name: Exscientia AI Ltd
Full Title: A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.
Medical condition: advanced solid tumors
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2022-002407-37 Sponsor Protocol Number: BET-PSMA-121 Start Date: 2023-05-22
Sponsor Name: Blue Earth Therapeutics Limited
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
Population Age: Adults, Elderly Gender: Male
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003398-51 Sponsor Protocol Number: R-Pola-Glo Start Date: 2023-05-16
Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in...
Medical condition: aggressive large B-cell lymphoma
Disease: Version SOC Term Classification Code Term Level
20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001781-35 Sponsor Protocol Number: UKER-BC007-01 Start Date: 2023-05-16
Sponsor Name: Universitätsklinikum Erlangen
Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients...
Medical condition: Post-COVID syndrome
Disease: Version SOC Term Classification Code Term Level
24.0 100000004862 10085505 Post-COVID syndrome LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2023-000135-76 Sponsor Protocol Number: ACE-01-22 Start Date: 2023-05-15
Sponsor Name: Adamed Pharma S.A.
Full Title: Therapeutic Equivalence Study of Twice Daily Acetylsalicylic Acid Tablets 50 mg Compared to Once Daily Acetylsalicylic Acid Tablets 100 mg in Adult Patients Coronary Artery Disease (CAD) or Symptom...
Medical condition: Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) or after Acute Coronary Syndrome (ACS)
Disease: Version SOC Term Classification Code Term Level
20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
21.1 100000004866 10067825 Peripheral arterial disease LLT
20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren